Security key
92337C203
Verastem, Inc. - Common stock, $0.0001 par value per share (VSTM)
CUSIP: 92337C203
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common stock, $0.0001 par value per share
- Total 13F shares
- 52,579,871
- Total 13F value
- $218,248,088
- Share change
- +9,310,109
- Put/Call ratio
- 49%
- SEC-reported price per share
- $4.15
- Number of holders
- 108
- Value change
- +$27,001,542
- Number of buys
- 74
- Number of sells
- 36
- Shares outstanding
- 90,515,464
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
108
Top holders
10
VSTM full security history
Ownership snapshot
Full 13F holder table
Verastem, Inc. SEC filings
Verastem, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of VSTM - Verastem, Inc. - Common stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Capital Master Fun...
Disclosed value leader
BALYASNY ASSET MANAGEMENT...
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 7.3%
13D/G row: Soleus Capital Master Fund, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Soleus Capital Master Fund, L.P. leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Soleus Capital Master Fund, L.P.'s linked filing trail.
Comparable ownership
Top 5
Soleus Capital Master Fund, L.P.
7.3%
Orin Hirschman
3.6%
ORBIMED ADVISORS LLC
2.4%
Alyeska Investment Group, L.P.
2.1%
Soleus Private Equity Fund III, L.P.
1.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. |
13D/G
Soleus Capital Management, L.P.
|
7.3%
|
$23,421,337
3,350,692 shares
|
$0 | 31 Dec 2024 |
| Orin Hirschman |
13D/G
|
3.6%
|
$8,298,970
2,003,179 shares
|
-$2,960,715 | 30 Jun 2025 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
2.4%
from 13D/G
|
$17,260,561
2,862,448 shares
|
— | 31 Mar 2025 |
| Alyeska Investment Group, L.P. |
13D/G
|
2.1%
|
$6,990,000
1,000,000 shares
|
$0 | 31 Dec 2024 |
| Soleus Private Equity Fund III, L.P. |
13D/G
Soleus Capital Management, L.P.
|
1.8%
|
$6,541,375
935,819 shares
|
$0 | 31 Mar 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
5.3%
|
$28,871,489
4,787,975 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
108
Shares
52,579,871
Rows available
108
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
98
Q2 2025 holders
108
Holder diff
10
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|